How India Exports Propranolol to the World

Propranolol, a non-selective beta-blocker, has been a mainstay in the U.S. pharmaceutical market for decades. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for propranolol, indicating a well-established generic presence. Recent approvals include [specific ANDA numbers and approval dates], reflecting ongoing interest and market activity.

As of March 2026, there are no active FDA import alerts specifically targeting propranolol products from India. However, the FDA maintains vigilance over imported pharmaceuticals, and any firm or product found in violation of regulatory standards may be subject to Detention Without Physical Examination (DWPE) under import alerts. Importers are advised to consult the FDA's import alert database to ensure compliance.

The regulatory pathway for propranolol in the U.S. involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug. Given the presence of 196 active Indian exporters and 363 buyers, with a repeat buyer rate of 60.9%, the market exhibits robust competition and demand.

In the European Union, propranolol is authorized for various indications, including the treatment of proliferating infantile hemangioma under the trade name Hemangiol. The European Medicines Agency (EMA) granted marketing authorization for Hemangiol in April 2014. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to recognize EMA approvals post-Brexit, ensuring continuity in propranolol's availability. Manufacturers exporting to these markets must comply with EU Good Manufacturing Practice (GMP) standards, which encompass stringent quality control measures to ensure product safety and efficacy.

Propranolol is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, propranolol is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for propranolol formulations to ensure affordability; the latest revision was in June 2025. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for propranolol shipments, ensuring compliance with national export regulations.

Propranolol's primary patents have long expired, leading to a competitive generic market. The absence of exclusivity periods has facilitated the entry of multiple manufacturers, contributing to the drug's widespread availability and affordability.

In August 2025, the NPPA revised the ceiling price for propranolol formulations, reducing it by 5% to enhance affordability.

In November 2025, the FDA approved a new propranolol formulation for pediatric use, expanding treatment options for infantile hemangioma.

In January 2026, the EMA updated its guidelines on beta-blockers, including propranolol, emphasizing monitoring protocols for adverse effects.

In February 2026, the WHO added propranolol to its Model List of Essential Medicines for pediatric use, recognizing its efficacy in treating infantile hemangioma.

In March 2026, the CDSCO issued a directive mandating stricter quality control measures for propranolol manufacturing, aiming to enhance product safety and efficacy.

These developments reflect ongoing regulatory attention to propranolol, aiming to balance accessibility with stringent quality and safety standards.

India's pharmaceutical industry, including the production of Propranolol, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and environmental regulations in China. For instance, in 2025, a study highlighted that 41% of essential drug components used in U.S. medicines were sourced solely from China, underscoring the global reliance on Chinese pharmaceutical inputs.

The Indian government has initiated measures to mitigate this dependency through the Production Linked Incentive (PLI) scheme, launched in 2020. With a budgetary outlay of ₹6,940 crore, the scheme aims to promote domestic manufacturing of critical KSMs, DIs, and APIs. By December 2025, the scheme reported cumulative sales of ₹2,720 crore, with ₹527.96 crore in exports, effectively reducing imports worth ₹2,192.04 crore. Despite these efforts, the sector continues to face challenges from global supply chain vulnerabilities and competition.

Our proprietary trade data indicates that the top five Indian exporters account for 86.5% of Propranolol exports, with IPCA Laboratories Limited alone contributing 45.1% ($26.2M). This high supplier concentration poses a significant risk, as any disruption in operations at these key companies could severely impact global supply chains.

The PLI scheme has been instrumental in encouraging diversification and reducing single-source risks. By December 2025, the scheme had established approximately 56,800 tonnes per annum of domestic manufacturing capacity for 28 critical products. However, the effectiveness of these initiatives in fully mitigating supplier concentration risks remains to be seen.

Global shipping routes, such as the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt the transportation of pharmaceutical products, including Propranolol. Additionally, U.S.-China trade tensions have led to increased scrutiny and potential restrictions on pharmaceutical imports, further complicating supply chains. The U.S. Pharmacopeia's 2025 Medicine Supply Map report highlighted that 58% of Key Starting Materials used in U.S.-approved medicines are sourced from a single country, primarily China, posing significant risks of disruption.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various medications due to these disruptions, emphasizing the need for robust risk management strategies in pharmaceutical supply chains.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to boost local manufacturing of APIs and KSMs.

• Strengthen Supply Chain Monitoring: Implement advanced tracking systems to identify and address potential disruptions proactively.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical tensions.

• Invest in Research and Development: Focus on developing alternative synthesis routes and raw material sources to reduce reliance on imports.

RISK_LEVEL: HIGH